Scholar Rock Holding (SRRK) Preferred Stock Liabilities (2017)

Scholar Rock Holding (SRRK) recorded quarterly Preferred Stock Liabilities of $109.2 million in Q4 2017.

Scholar Rock Holding (SRRK) Preferred Stock Liabilities (2017) Analysis & Trends

Scholar Rock Holding's Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $109.2 million for Q4 2017.

In Q4 2017, Preferred Stock Liabilities changed N/A year-over-year to $109.2 million; the TTM figure through Dec 2017 stood at $109.2 million (changed N/A YoY), while the FY2017 annual figure was $109.2 million, changed N/A from the prior year.
Preferred Stock Liabilities was $109.2 million for Q4 2017 at Scholar Rock Holding.
In the past five years, Preferred Stock Liabilities ranged from a high of $109.2 million in Q4 2017 to a low of $109.2 million in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	-
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Scholar Rock Holding	5.62 Bn	5.14 Bn	-	-

Download Data

Date	Value
Dec 31, 2017	109.23 Mn